GG 1978 SICAF SIF S.A.
CIK: 0001814891
Associated companies
Transaction History
| RPRX | ▼ Sell | Open Market | 154,154 | $6.5M | 9/15/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 190,860 | $8.1M | 9/14/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 154,154 | $6.5M | 9/15/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 190,860 | $8.1M | 9/14/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend
Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.